ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

Identification and Management of People With Elevated Breast Cancer …

Sarina Schrager

Male Breast Cancer

Kathryn J. Ruddy

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

SABCS 2024 Summary: Addressing Pathologic and Therapeutic Challenges…

2024 SABCS Annual Meeting Insights Hub

L. Tabar

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Benefits of Oral Formulations in HR+/HER2- mBC: Reducing Time Toxici…

Priya Tiwari

ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer

2024 ESMO Annual Meeting Insights Hub

J. Huober

ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- …

2024 ESMO Annual Meeting Insights Hub

K. Jhaveri

ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cancer"

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney, H. Rugo

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

ESMO Breast 2024 Summary: "Community Oncologists Highlights"

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney, H. Rugo

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo

SABCS 2024 Review: De-Escalation of Local-Regional Treatment in Olde…

Yale Cancer Center

M. Moran

ctDNA Monitoring for Breast Cancer at High Risk of Recurrence: Inter…

Yukinori Ozaki

3L Treatment Approaches in HER2+ mBC: Current Gaps and Advancements

Arif Ali Awan

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

SABCS 2024 Review: Evaluating the Role of Adjuvant ET in Low-Risk DC…

Yale Cancer Center

M. Moran